Porcine Vaccines Market is Projected to Expand at a Compounded Annual Growth Rat

Posted by Sachin Darakhe on October 4th, 2019

The global porcine vaccines market was valued at US$ 1,784.0 Mn in 2016 and is projected to expand at a compounded annual growth rate (CAGR) of 7.0% from 2017 to 2025, according to a new report published by Transparency Market Research (TMR) titled “Porcine Vaccines Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2017–2025.” The report suggests that increase in the number of hog/swine farms and rise in the demand for porcine meat and gelatin are expected to drive the global porcine vaccines market from 2017 to 2025. North America and Europe are projected to dominate the global market during the forecast period, owing to increase in the demand for swine meat and high adoption of porcine vaccines for instant treatment planning by veterinary doctors as well as researchers.

The market in Asia Pacific is projected to expand at a rapid CAGR during the forecast period. Growth of the market in Asia Pacific can be attributed to large volume of pig cultivation in countries of Southeast Asia, rising population of pigs requiring treatment for various diseases such as diarrhea and swine influenza, and growth of biotechnology firms producing swine vaccines in the region. The market for porcine vaccines in Latin America is likely to expand at a moderate growth rate during the forecast period.

Request a Sample of Porcine Vaccines Market Report

https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=42440

• Technological Advancements in Porcine Vaccines to fuel Global Market

The global porcine vaccines market is projected to be driven by value-added features offered by various animal health care companies in order to streamline the day-to-day workflow and increase the revenue. Porcine vaccines provide a wide range of benefits for the treatment of swine diseases. Key players offering porcine vaccines are coming up with vaccines with value-added features such as effective recombinant vaccines, DNA vaccines, and conjugate vaccines. These new features or technological advancements in vaccines reduce the overall vaccination cost and thus, improve the overall effectiveness and efficiency of swine production practices.

Companies are focusing on the development of vaccines for major diseases such as African swine flu and porcine circovirus associated disease (PCVAD). Other factors such as growth of biotechnology companies engaged in research and development of porcine vaccines, rise in investments in R&D, and growing government initiatives for funding societies for growth of the agriculture field are fueling the global porcine vaccines market.